FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue

A recently published Warning Letter from the US Food and Drug Administration (FDA) to OraLabs Inc. (March 2026) once again highlights a recurring pattern in FDA inspections: inadequate root cause analysis (RCA) and the resulting CAPA actions.

At the heart of the findings is a classic GMP violation of 21 CFR 211.192: "Your firm failed to thoroughly investigate any unexplained discrepancy or failure…".
The FDA found that investigations carried out into microbiological deviations frequently did not include a sound root cause analysis and that the resulting CAPAs were inadequate. In several cases, deviations were simply 'invalidated' without sufficient scientific justification.

The following points were particularly highlighted:

• Causes were often inconclusive or left unresolved
• Investigations did not consider all potential influencing factors (e.g. manufacturing process, environment, materials)
• Risks were downplayed, even though clear microbiological findings were available
• Lots were released and placed on the market despite unclear causes

The Warning Letter clearly shows that the FDA continues to scrutinise very closely whether companies carry out systematic and scientifically sound root cause analyses (RCA) and derive effective CAPAs that actually prevent recurrence.